[HTML][HTML] Immune system dysregulation during spaceflight: potential countermeasures for deep space exploration missions

BE Crucian, A Choukèr, RJ Simpson, S Mehta… - Frontiers in …, 2018 - frontiersin.org
Recent studies have established that dysregulation of the human immune system and the
reactivation of latent herpesviruses persists for the duration of a 6-month orbital spaceflight …

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

H Yousefi, L Mashouri, SC Okpechi, N Alahari… - Biochemical …, 2021 - Elsevier
The outbreak of a novel coronavirus (SARS-CoV-2) has caused a major public health
concern across the globe. SARS-CoV-2 is the seventh coronavirus that is known to cause …

[HTML][HTML] Herpes virus reactivation in astronauts during spaceflight and its application on earth

BV Rooney, BE Crucian, DL Pierson… - Frontiers in …, 2019 - frontiersin.org
Latent herpes virus reactivation has been demonstrated in astronauts during shuttle (10–16
days) and International Space Station (≥ 180 days) flights. Following reactivation, viruses …

Sphingosine 1-phosphate receptor modulators for multiple sclerosis

R Roy, AA Alotaibi, MS Freedman - CNS drugs, 2021 - Springer
Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-
class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral …

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment

L Klotz, J Havla, N Schwab, R Hohlfeld… - Therapeutic …, 2019 - journals.sagepub.com
In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS)
owing to the approval of a number of new drugs with very distinct mechanisms of action. All …

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

AM Arvin, JS Wolinsky, L Kappos, MI Morris… - JAMA …, 2015 - jamanetwork.com
Importance Varicella-zoster virus (VZV) infections increasingly are reported in patients with
multiple sclerosis (MS) and constitute an area of significant concern, especially with the …

Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis

R Martin, M Sospedra, M Rosito… - European journal of …, 2016 - Wiley Online Library
Multiple sclerosis (MS) is the most common inflammatory disorder of the central nervous
system (CNS) in young adults. When MS is not treated, it leads to irreversible and severe …

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and …

C Tur, AL Dubessy, S Otero-Romero… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica
spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease …

[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …

G Redelman-Sidi, O Michielin, C Cervera, C Ribi… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients

PS Rommer, UK Zettl - Expert opinion on pharmacotherapy, 2018 - Taylor & Francis
Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative
disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing …